Geode Capital Management LLC Lowers Stock Position in AlloVir, Inc. (NASDAQ:ALVR)

Geode Capital Management LLC cut its stake in shares of AlloVir, Inc. (NASDAQ:ALVR) by 9.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 585,548 shares of the company’s stock after selling 61,929 shares during the quarter. Geode Capital Management LLC owned approximately 0.51% of AlloVir worth $474,000 at the end of the most recent reporting period.

Separately, Cubist Systematic Strategies LLC boosted its position in shares of AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock worth $36,000 after purchasing an additional 30,072 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Price Performance

Shares of ALVR stock opened at $0.44 on Monday. AlloVir, Inc. has a one year low of $0.40 and a one year high of $1.05. The company’s fifty day moving average price is $0.54 and its 200-day moving average price is $0.69. The company has a market capitalization of $50.75 million, a price-to-earnings ratio of -0.50 and a beta of 0.65.

AlloVir (NASDAQ:ALVR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.